surmount-1 tirzepatide non-diabetic weight loss Gastrointestinal tolerability and reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 Weight reduction with different doses

The drug is now also approved for obstructive sleep apnea in adults with obesity, where it cut the apnea-hypopnea index by about half in the SURMOUNT-OSA trial

Following its clinical trials and approval, the impact of tirzepatide on patients has been profound

Monitoring Response Weight trends, appetite changes, and side effects are often monitored closely during the first several weeks to guide adjustments

The best reference point is oral semaglutide, because it is the only GLP-1 receptor agonist that has been successfully formulated as an oral tablet and approved by the FDA

Weight Loss Beyond diabetes management, tirzepatide is also effective for weight loss

Tirzepatide injections are available through supervised medical weight loss clinics